Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PEN Stock Forecast 2026-2027
$319.47
Current Price
$12.51B
Market Cap
Buy 17
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to PEN Price Targets
+21.5%
To High Target of $388.00
+8.6%
To Median Target of $347.00
-41.8%
To Low Target of $186.00
PEN Price Momentum
+0.8%
1 Week Change
+2.4%
1 Month Change
+29.4%
1 Year Change
+2.8%
Year-to-Date Change
-1.7%
From 52W High of $325.02
+44.4%
From 52W Low of $221.26
📊 TOP ANALYST CALLS
Did PEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Penumbra is one of their latest high-conviction picks.
Latest PEN Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, PEN has a bullish consensus with a median price target of $347.00 (ranging from $186.00 to $388.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $319.47, the median forecast implies a 8.6% upside. This outlook is supported by 17 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Mike Matson at Needham, projecting a 21.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PEN Analyst Ratings
17
Buy
1
Hold
1
Sell
PEN Price Target Range
Low
$186.00
Average
$347.00
High
$388.00
Current: $319.47
Latest PEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 5, 2026 | B of A Securities | Travis Steed | Buy | Maintains | $370.00 |
| Dec 18, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $370.00 |
| Dec 18, 2025 | JP Morgan | Robert Marcus | Overweight | Upgrade | $370.00 |
| Dec 17, 2025 | Needham | Mike Matson | Buy | Maintains | $388.00 |
| Dec 17, 2025 | Canaccord Genuity | Jason Mills | Buy | Maintains | $359.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Buy | Upgrade | $350.00 |
| Nov 6, 2025 | JP Morgan | Robert Marcus | Neutral | Maintains | $275.00 |
| Nov 6, 2025 | Canaccord Genuity | Jason Mills | Buy | Maintains | $355.00 |
| Oct 27, 2025 | BTIG | Ryan Zimmerman | Buy | Reiterates | $320.00 |
| Oct 27, 2025 | Needham | Mike Matson | Buy | Reiterates | $326.00 |
| Oct 15, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $300.00 |
| Oct 8, 2025 | Needham | Mike Matson | Buy | Upgrade | $326.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $285.00 |
| Sep 2, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Initiates | $300.00 |
| Jul 31, 2025 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Maintains | $266.00 |
| Jul 30, 2025 | Truist Securities | David Rescott | Buy | Maintains | $310.00 |
| Jul 30, 2025 | UBS | Priya Sachdeva | Buy | Maintains | $335.00 |
| Jul 30, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $290.00 |
| Jul 30, 2025 | Canaccord Genuity | Jason Mills | Buy | Maintains | $350.00 |
| Jul 30, 2025 | Baird | David Rescott | Outperform | Maintains | $285.00 |
Penumbra Inc. (PEN) Competitors
The following stocks are similar to Penumbra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Penumbra Inc. (PEN) Financial Data
Penumbra Inc. has a market capitalization of $12.51B with a P/E ratio of 77.0x. The company generates $1.33B in trailing twelve-month revenue with a 12.3% profit margin.
Revenue growth is +17.8% quarter-over-quarter, while maintaining an operating margin of +13.8% and return on equity of +13.3%.
Valuation Metrics
Market Cap
$12.51B
Enterprise Value
$12.37B
P/E Ratio
77.0x
PEG Ratio
1.4x
Price/Sales
9.5x
Growth & Margins
Revenue Growth (YoY)
+17.8%
Gross Margin
+67.8%
Operating Margin
+13.8%
Net Margin
+12.3%
EPS Growth
+55.3%
Financial Health
Cash/Price Ratio
+3.8%
Current Ratio
6.7x
Debt/Equity
16.0x
ROE
+13.3%
ROA
+6.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Penumbra Inc. (PEN) Business Model
About Penumbra Inc.
What They Do
Develops innovative medical devices for healthcare.
Business Model
Penumbra Inc. generates revenue through the development and commercialization of specialized medical devices aimed at interventional therapies. The company focuses on minimally invasive solutions for critical medical conditions, such as stroke and peripheral artery diseases, thereby enhancing patient outcomes and driving sales through healthcare providers and hospitals.
Additional Information
Founded in 2004 and headquartered in Alameda, California, Penumbra is committed to advancing healthcare technologies and plays a crucial role in the medical device industry. Its customer-centric approach and innovative products support the broader healthcare ecosystem in improving care and saving lives.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
4,500
CEO
Mr. Adam Elsesser J.D.
Country
United States
IPO Year
2015
Website
www.penumbrainc.comPenumbra Inc. (PEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
CLPBY vs. PEN: Which Stock Is the Better Value Option?
CLPBY vs. PEN: Which Stock Is the Better Value Option?
Jan 12, 2026
By Zacks Equity Research
Tale of the Tape
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jan 12, 2026
By Zacks Equity Research
Tale of the Tape
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Jan 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Penumbra (PEN) shows strong financial growth potential, suggesting it may outperform the market.
Why It Matters
Penumbra's strong financial growth suggests potential for higher returns, making it an attractive option for investors seeking outperforming stocks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can help investors select strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in selecting high-performing stocks, potentially enhancing portfolio returns and optimizing investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Penumbra, Inc. (NYSE: PEN) will present at the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 2026.
Why It Matters
Penumbra's presentation at a major investment conference can influence investor sentiment, provide insights into company strategy, and affect stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PEN's thrombectomy portfolio expansion and international growth are driving momentum, though foreign exchange and macroeconomic pressures present risks.
Why It Matters
PEN's thrombectomy portfolio expansion and international growth signal potential revenue increases, but currency fluctuations and macroeconomic challenges could impact profitability.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Stocks At New Highs: Industrials Allient, Wabtec And A Health Care Name Trade In Or Near Buy Zones
24 days ago
Quick Summary
Allient, Wabtec, and Penumbra reached new stock highs on Friday, indicating strong performance in the industrial and health technology sectors.
Why It Matters
New highs in stocks like Allient, Wabtec, and Penumbra indicate strong performance in key sectors, signaling potential growth and positive market sentiment, attracting investor interest.
Source: Investors Business Daily
Market Sentiment:
Positive
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
1 month ago
Quick Summary
Penumbra, Inc. (PEN) presented at the Piper Sandler 37th Annual Healthcare Conference, sharing updates on its business and products.
Why It Matters
Penumbra's presentation at a major healthcare conference can signal potential growth or innovation, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PEN Stock
What is Penumbra Inc.'s (PEN) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Penumbra Inc. (PEN) has a median price target of $347.00. The highest price target is $388.00 and the lowest is $186.00.
Is PEN stock a good investment in 2026?
According to current analyst ratings, PEN has 17 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $319.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PEN stock?
Wall Street analysts predict PEN stock could reach $347.00 in the next 12 months. This represents a 8.6% increase from the current price of $319.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Penumbra Inc.'s business model?
Penumbra Inc. generates revenue through the development and commercialization of specialized medical devices aimed at interventional therapies. The company focuses on minimally invasive solutions for critical medical conditions, such as stroke and peripheral artery diseases, thereby enhancing patient outcomes and driving sales through healthcare providers and hospitals.
What is the highest forecasted price for PEN Penumbra Inc.?
The highest price target for PEN is $388.00 from Mike Matson at Needham, which represents a 21.5% increase from the current price of $319.47.
What is the lowest forecasted price for PEN Penumbra Inc.?
The lowest price target for PEN is $186.00 from at , which represents a -41.8% decrease from the current price of $319.47.
What is the overall PEN consensus from analysts for Penumbra Inc.?
The overall analyst consensus for PEN is bullish. Out of 22 Wall Street analysts, 17 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $347.00.
How accurate are PEN stock price projections?
Stock price projections, including those for Penumbra Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 5:05 AM UTC